About Lymphokine-activated killer T-cell-originated protein kinase
Lymphokine-activated killer T-cell-originated protein kinase (PBK) is a protein
from Homo sapiens identified by UniProt accession
Q96KB5, 322 residues long.
MolForge cross-references it against 0 known binders and
200 disease associations.
Target properties
| Protein name | Lymphokine-activated killer T-cell-originated protein kinase |
|---|
| UniProt accession | Q96KB5 |
|---|
| Gene | PBK |
|---|
| Organism | Homo sapiens |
|---|
| Length | 322 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (200)
Diseases linked to this target (Open Targets).
- body height · score 0.26
- blood protein measurement · score 0.18
- neoplasm · score 0.11
- cancer · score 0.11
- erythrocyte count · score 0.11
- hepatocellular carcinoma · score 0.11
- non-small cell lung carcinoma · score 0.10
- esophageal squamous cell carcinoma · score 0.10
- glioblastoma multiforme · score 0.10
- renal cell carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96KB5-F1 | alphafold | PREDICTED | 84.40 | — |
Amino-acid sequence (322 residues)
MEGISNFKTP SKLSEKKKSV LCSTPTINIP ASPFMQKLGF GTGVNVYLMK RSPRGLSHSP WAVKKINPIC NDHYRSVYQK RLMDEAKILK SLHHPNIVGY RAFTEANDGS LCLAMEYGGE KSLNDLIEER YKASQDPFPA AIILKVALNM ARGLKYLHQE KKLLHGDIKS SNVVIKGDFE TIKICDVGVS LPLDENMTVT DPEACYIGTE PWKPKEAVEE NGVITDKADI FAFGLTLWEM MTLSIPHINL SNDDDDEDKT FDESDFDDEA YYAALGTRPP INMEELDESY QKVIELFSVC TNEDPKDRPS AAHIVEALET DV
Explore Lymphokine-activated killer T-cell-originated protein kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets